PG
ONCT

Pendal Group’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Pendal Group’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-343
Closed -$735K – 493
2018
Q2 		$735K Buy
+343
New +$870K 0.01% 340

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pendal Group's ONCT Position: Q3 2018 in Review

Pendal Group sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2018, closing a stake of 343 shares — an estimated $735K sold.

Pendal Group first reported a position in ONCT in Q2 2018 and held it in 1 quarter. The position peaked at $735K in Q2 2018. 48 funds tracked by Wall St. Rank hold ONCT as of Q3 2018.

  • Pendal Group reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Pendal Group sold 343 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $735K.
  • Pendal Group first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Pendal Group's Oncternal Therapeutics, Inc. Common Stock position peaked at $735K in Q2 2018.
  • 48 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Pendal Group's 13F filing for Q3 2018, filed 5 Nov 2018.